MedImmune
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, MedImmune sits in the top decile of US sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count).
MedImmune: 210 sponsored US clinical trials, none currently recruiting.
MedImmune sponsors 210 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 185 completed. 27 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 9 trials.
Top-decile sponsor footprint
MedImmune ranks in the top decile of sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
185 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
210 total, page 1 of 5
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
NCT04522323
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
NCT04068610
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
NCT03381274
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT03530397
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
NCT02671435
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
NCT02519348
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
NCT01843374
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
NCT04261075
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
NCT03889275
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
NCT04091373
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
NCT04019561
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
NCT03946800
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
NCT03794544
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
NCT03811652
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
NCT03822351
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
NCT03654313
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
NCT03625778
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
NCT03611556
D2560C00015 FluMist Annual Safety Study 2018
NCT03564444
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
NCT03489525
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
NCT03385369
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease
NCT03351738
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382
NCT03341013
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
NCT03347968
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
NCT03162224
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
NCT03158038
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
NCT03143101
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
NCT03106428
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
NCT03089645
Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
NCT03004638
Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884
NCT03001297
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
NCT02991911
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.
NCT02878330
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
NCT02900157
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
NCT02549651
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
NCT02743117
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
NCT02705482
Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
NCT02696902
Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects
NCT02669667
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
NCT02603952
To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
NCT02601560
A Study in Adult Subjects With Select Advanced Solid Tumors
NCT02583165
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
NCT02556463
A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes
NCT02524782
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
NCT02508194
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
NCT02576548
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
NCT02525094
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
NCT02503774
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
NCT02334306
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
NCT02473510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 58 |
| Phase 3 | 12 |
| Phase 4 | 15 |
How the MedImmune early-phase archive is shaped
210 indexed studies, none listed as recruiting (0% open); 185 completed (88%).
Phase mix: 27 late (III/IV) vs 164 early (I/II) (early-phase heavy).
Top condition: Healthy (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
MedImmune: archived-pipeline peers nationwide
Peers matched on 210 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
MedImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 210 archived trials
- OHSU Knight Cancer Institute · 211 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this MedImmune page
210 registered trials is a research-attention snapshot, not an endorsement of MedImmune or any single study.
- None of MedImmune's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition MedImmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MedImmune pipeline card: 210 registered trials from official public datasets.Report a data error.